To raise greater awareness of neuroendocrine tumor (NET) cancers the first annual Worldwide NET Cancer Awareness Day is being planned for Wednesday, November 10, 2010. In preparation for this unique day, a proclamation has been created by the World NET Community Steering Committee. The World NET Community encourages “patients, caregivers, healthcare professionals, as well as the wider community, to join with us as we work together to raise awareness about NET cancers and the need for timely diagnosis and access to optimal treatment and care.”
Representing 11 countries and 4 continents, the World NET Community Steering Committee brings together NET cancer and carcinoid support and advocacy groups from around the world. Pictured below are the Steering Committee members.
Bottom row, left to right:
Grace Goldstein, The Carcinoid Cancer Foundation (CCF), United States
Katharina Mellar, Bundesweites Netzwerk Neuroendokrine Tumoren (NeT) e. V., Germany
Maryann Wahmann, Carcinoid Cancer Awareness Network (CCAN), United States
Agneta H-Franzen, CARPA (The Carcinoid Patient Association), Sweden
Inge Engle, Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e. V., Germany
Maureen Coleman, Carcinoid-Neuroendocrine Tumour Society – Canada (CNETS-Canada), Canada
John Leyden, MD, The Unicorn Foundation, Australia
Evgenia Adarska, APOZ and Friends, Bulgaria
Tore Asbu, CarciNor, foreningen for personer med nevroendokrin kreft, Norway
Top row, left to right:
Jaroslaw Cwikla, MD, Stowarzyszenie Pacjentow Osob Wspierajacych Chroych na Guzy Neuroendokrynne, Poland
John Hogervorst, Stichting Doorgang, Netherlands
William Claxton, Carcinoid & Neuroendocrine Tumor Society (CNETS SG) Singapore
Robert Wahmann, Carcinoid Cancer Awareness Network (CCAN), United States
Kari Brendtro, NANETS (North American NeuroEndocrine Tumor Society), United States
Maia Sissions, NET Patient Foundation: Incorporating Living with Carcinoid, United Kingdom
Catherine Bouvier, NET Patient Foundation: Incorporating Living with Carcinoid, United Kingdom
Ralitsa Bashliyska, MD, APOZ and Friends, Bulgaria
An early version of the Proclamation was signed by all who attended the Carcinoid Cancer Foundation’s Symposium for patients, family, friends, and healthcare professionals, “Determining Molecular Signature: A Guide for Targeted Therapy of Neuroendocrine Tumors,” a presentation by Michael J. Demeure, MD, MBA, on his cutting-edge research, at Mt. Sinai Hospital in New York City in April. Proclamations will be signed at upcoming events for carcinoid and neuroendocrine tumor (NET) cancer patients worldwide.
